Pilot Grant Program

The purpose of the Institute for Human Infections and Immunity (IHII) Pilot Grant Program is to stimulate the development of new research initiatives in strategic areas of infectious diseases and immunology aimed at capitalizing on new research and funding opportunities and strengthening overall IHII programs and goals.

Call for FY26 IHII Grant Application 

The purpose of the IHII Pilot Grant Program is to enhance funding and success rates of extramural grant in strategic area of infectious diseases and immunology.  

ELIGIBILITY: Any UTMB employee eligible to submit extramural grant applications is encouraged to apply.  New faculty or those developing interests related to infection and immunity are encouraged to seek membership in the IHII before applying.  Progress reports for past IHII grants will be reviewed to assess the PI's productivity.  Investigators may submit more than one application for consideration; however, no more than one IHII supported grant will be awarded.  The PI may not have already received funding for the proposed project from other intramural or extramural resources; all related, pending proposals must be disclosed in your application. 

Proposal may be submitted by June 30, 2025, at 9AM. Please send a single PDF file to Ms. Marcela Lopez (mblopez@utmb.edu).

FY2025 IHII Pilot Grant 

PICo-PI(s)TypeTitle
Adam, Awada KareemWang, TianPilotLongitudinal analysis of T and B cell responses in chikungunya virus asymptomatic and symptomatic infection
Bao, XiaoyongXiang Fang, Keidi Spratt, Wenzhe WuPilottRNA-derived RNA Fragments and Their Potential Role in Mediating Multiple Sclerosis Associated with Epstein-Barr Virus
Bovendo, FaustherTian Wang, Awad AdamPilotImproving existing treatments and vaccines against mpox disease
Melby, PeteGugala, ZbigniewBridgingGut microbiota, inflammation, and bone growth in a model of childhood malnutrition
Terasaki, Kaori PilotCis-acting replication signal for SARS-CoV-2 defective RNA replication
Torres, Alfredo PilotVirus-like particles as vaccine platform against melioidosis disease